About Event
Be Part of Our Mission to Revitalize the Macrophage Community!
This is a premier gathering for developers of macrophage-directed therapies and stands as a pivotal hub for C-Level Executives, Vice Presidents, and Directors. In October, prepare to explore all facets of macrophage therapies, from addressing delivery methods and macrophage-specific biological challenges, to discussing innovative targets and considering iPSC and HSC-derived cell sources and manufacturing processes, all with the aim of advancing toward clinical application.
Join us to:
 |
Explore CAR-M for solid tumor immunotherapy with insights into the clinical program of Anti-HER2 CAR-M ex vivo cell therapy and direct in vivo CAR reprogramming using mRNA withCarisma Therapeutics |
|
Navigate the evolving range of novel macrophage targets to rekindle interest in the newest developments in the space with Pathios Therapeutics, Elpiscience Biopharmaceuticals, Voro Therapeutics, and ALX Oncology |
|
Assess the suitability of a diverse range of models for macrophage therapeutics and compare their advantages with the University of California, San Diego |
|
Build a robust biomarker pipeline and discuss key considerations for biomarker selection to ensure accurate treatments for individual patients with John Hopkins School of Medicine and the Whitehead Institute |
|
Unlock investor perspectives and hear their requirements for funding with 20/20 Healthcare Partners |
|
Investigate the impact of macrophage-directed therapies in indications spanning inflammatory diseases, autoimmunity, CNS disease, and beyond to roadmap their potential with Attralus, Resolution Therapeutics, and Shoreline Biosciences |
Download the Full Agenda for More Information on:
-
-
-
- 28+ Macrophage Expert Speakers
- 3 Interactive Deep-Dive Workshops
- 8+ Hours of Industry Networking
- & Much More!
-
-
